Targeting ABL and SRC kinases in chronic myeloid leukemia: Experience with dasatinib

Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Mutations within the ABL kinase domain and overexpression of SRC family kinases have been identified among the known mechanisms of resistance to imatinib in chronic myeloid leukemia (CML). The development of agents with dual inhibitory activity against SRC and ABL kinases is one approach to overcome imatinib resistance. One such agent, dasatinib (formerly BMS-354825), is approximately 300-fold more potent against BCR-ABL than imatinib, and is active against all tested ABL mutant isoforms, except for T315I. Dasatinib has demonstrated high efficacy in Phase I and II studies in patients with CML following failure of imatinib therapy. Studies exploring the efficacy of dasatinib as front-line therapy in patients with BCR-ABL-expressing hematologic malignancies are underway.

Original languageEnglish (US)
Pages (from-to)655-665
Number of pages11
JournalFuture Oncology
Volume2
Issue number6
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphotransferases
Hematologic Neoplasms
Protein Isoforms
Mutation
Imatinib Mesylate
Dasatinib
Therapeutics

Keywords

  • BCR-ABL
  • Chronic myeloid leukemia
  • Dasatinib
  • Resistance
  • SRC
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting ABL and SRC kinases in chronic myeloid leukemia : Experience with dasatinib. / Quintás-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge.

In: Future Oncology, Vol. 2, No. 6, 01.12.2006, p. 655-665.

Research output: Contribution to journalArticle

Quintás-Cardama, Alfonso ; Kantarjian, Hagop ; Cortes, Jorge. / Targeting ABL and SRC kinases in chronic myeloid leukemia : Experience with dasatinib. In: Future Oncology. 2006 ; Vol. 2, No. 6. pp. 655-665.
@article{84293f3c823d48e69d2cea147b598d8e,
title = "Targeting ABL and SRC kinases in chronic myeloid leukemia: Experience with dasatinib",
abstract = "Mutations within the ABL kinase domain and overexpression of SRC family kinases have been identified among the known mechanisms of resistance to imatinib in chronic myeloid leukemia (CML). The development of agents with dual inhibitory activity against SRC and ABL kinases is one approach to overcome imatinib resistance. One such agent, dasatinib (formerly BMS-354825), is approximately 300-fold more potent against BCR-ABL than imatinib, and is active against all tested ABL mutant isoforms, except for T315I. Dasatinib has demonstrated high efficacy in Phase I and II studies in patients with CML following failure of imatinib therapy. Studies exploring the efficacy of dasatinib as front-line therapy in patients with BCR-ABL-expressing hematologic malignancies are underway.",
keywords = "BCR-ABL, Chronic myeloid leukemia, Dasatinib, Resistance, SRC, Tyrosine kinase inhibitor",
author = "Alfonso Quint{\'a}s-Cardama and Hagop Kantarjian and Jorge Cortes",
year = "2006",
month = "12",
day = "1",
doi = "10.2217/14796694.2.6.655",
language = "English (US)",
volume = "2",
pages = "655--665",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Targeting ABL and SRC kinases in chronic myeloid leukemia

T2 - Experience with dasatinib

AU - Quintás-Cardama, Alfonso

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Mutations within the ABL kinase domain and overexpression of SRC family kinases have been identified among the known mechanisms of resistance to imatinib in chronic myeloid leukemia (CML). The development of agents with dual inhibitory activity against SRC and ABL kinases is one approach to overcome imatinib resistance. One such agent, dasatinib (formerly BMS-354825), is approximately 300-fold more potent against BCR-ABL than imatinib, and is active against all tested ABL mutant isoforms, except for T315I. Dasatinib has demonstrated high efficacy in Phase I and II studies in patients with CML following failure of imatinib therapy. Studies exploring the efficacy of dasatinib as front-line therapy in patients with BCR-ABL-expressing hematologic malignancies are underway.

AB - Mutations within the ABL kinase domain and overexpression of SRC family kinases have been identified among the known mechanisms of resistance to imatinib in chronic myeloid leukemia (CML). The development of agents with dual inhibitory activity against SRC and ABL kinases is one approach to overcome imatinib resistance. One such agent, dasatinib (formerly BMS-354825), is approximately 300-fold more potent against BCR-ABL than imatinib, and is active against all tested ABL mutant isoforms, except for T315I. Dasatinib has demonstrated high efficacy in Phase I and II studies in patients with CML following failure of imatinib therapy. Studies exploring the efficacy of dasatinib as front-line therapy in patients with BCR-ABL-expressing hematologic malignancies are underway.

KW - BCR-ABL

KW - Chronic myeloid leukemia

KW - Dasatinib

KW - Resistance

KW - SRC

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=33845614329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845614329&partnerID=8YFLogxK

U2 - 10.2217/14796694.2.6.655

DO - 10.2217/14796694.2.6.655

M3 - Article

C2 - 17155893

AN - SCOPUS:33845614329

VL - 2

SP - 655

EP - 665

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 6

ER -